Savara presents CHEST data before the FDA decision for Savara stock

Published on 10/20/2026 at 13:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Savara presented molgramostim data on October 12, 2026 for CHEST. Savara stock costs EUR 4.17 on October 20, 2026 before the November 22 FDA decision.

Regulatory timeline takes shape

The company scheduled two CHEST 2026 presentations on October 12, 2026.
Savara reported a USD 40.2 million net loss for the second quarter of 2026.
Savara stock was trading at EUR 4.17 at 1:40 p.m. CEST at Lang & Schwarz on October 20, 2026.
The FDA decision on molgramostim is scheduled for November 22, 2026.

SVRA, US8051111016, Illustration mit AI erstellt.

Savara Inc. (ISIN US8051111016) scheduled two CHEST 2026 presentations on October 12, 2026, while its stock was trading at EUR 4.17 at Lang & Schwarz on October 20, 2026 at 1:40 p.m. CEST. The company is using new molgramostim data to support the development case for its lead respiratory program, with a regulatory decision approaching.

CHEST presentations add data

According to Savara, the company presented an encore oral session on long-term Phase 3 IMPALA-2 data on October 20, 2026 and scheduled a poster presentation for October 21, 2026. Both sessions concern molgramostim in autoimmune pulmonary alveolar proteinosis.

The timing matters because Savara's U.S. application for molgramostim is under Priority Review. RTTNews lists November 22, 2026 as the FDA decision date after the review period was extended by three months.

What does the loss mean for launch readiness?

Savara reported a USD 40.2 million net loss for the second quarter of 2026, compared with a USD 37.3 million net loss in the first quarter, according to Quartr. The same presentation summary cited USD 173.0 million in cash and short-term investments as of June 30, 2026, giving the launch plan a financial counterweight to the continuing burn.

Next dates for Savara

The next scheduled company event is the October 21, 2026 CHEST poster session on molgramostim in patients with mild diffusion impairment. The next major regulatory date is November 22, 2026, when the FDA is due to act on the application.

Stock trades ahead of the decision

At Lang & Schwarz, Savara stock was trading at EUR 4.17 on October 20, 2026 at 1:40 p.m. CEST. On Nasdaq, the last quoted price was USD 4.63 at 4:00 p.m. ET on October 19, 2026; the U.S. quote had a 52-week range of USD 3.86 to USD 7.01 and a market capitalization of USD 951.3 million.

The further course of trading is shown by the continuously updated real-time quote of Savara stock.